Creatsas G C, Charalambidis V M, Zagotzidou E H, Anthopoulou H N, Michailidis D C, Aravantinos D I
First Department of Obstetrics and Gynaecology, University of Athens, Greece.
Clin Ther. 1993 Jul-Aug;15(4):662-71.
Twenty-one women (mean age, 35.3 years) with 2 to 4 episodes of vaginal candidosis in the last 6 months were included in the study to evaluate the efficacy and safety of itraconazole as short-term, as well as prophylactic, treatment of chronic candidosis. After clinical evaluation and laboratory confirmation of candidosis, 200 mg of itraconazole were given orally for 3 days. Twelve of the 21 patients were cured. The remaining nine repeated treatment, after which all were cured. All patients were entered in the maintenance phase, and received 200 mg of itraconazole the first day of the menstrual cycle for 6 months. One patient relapsed in the second month, but after taking 200 mg of itraconazole BID for 1 day she remained cured for the rest of the study period. All other patients remained cured for the 6 months of the maintenance period. Three months after the end of prophylactic therapy, 17 of 20 patients (85%) were clinically and mycologically cured. No adverse experiences were reported. It is concluded that itraconazole is an efficient and safe short-term treatment for chronic or recurrent vaginal candidosis. Moreover, the dose of 200 mg once monthly for 6 months proved to be a successful suppressive treatment.
21名在过去6个月内有2至4次阴道念珠菌病发作的女性（平均年龄35.3岁）被纳入该研究，以评估伊曲康唑作为慢性念珠菌病短期及预防性治疗的疗效和安全性。在对念珠菌病进行临床评估和实验室确诊后，口服200毫克伊曲康唑，持续3天。21名患者中有12名治愈。其余9名患者重复治疗，之后全部治愈。所有患者进入维持期，在月经周期的第一天服用200毫克伊曲康唑，持续6个月。1名患者在第二个月复发，但在服用200毫克伊曲康唑每日两次，共1天后，在研究期的剩余时间内保持治愈状态。所有其他患者在维持期的6个月内均保持治愈。预防性治疗结束3个月后，20名患者中有17名（85%）在临床和真菌学上治愈。未报告不良事件。结论是，伊曲康唑是慢性或复发性阴道念珠菌病的一种有效且安全的短期治疗方法。此外，每月一次200毫克，持续6个月的剂量被证明是一种成功的抑制性治疗方法。
